Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 · kind B2 · utility
90Cited by
67References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 14, 2008 |
| Grant date | Mar 13, 2012 |
| Priority date | — |
| Expiry date | Jul 2, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D409/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods of treating a disease selected from systemic sclerosis, rheumatoid arthritis, mastocytosis, and chronic eosinophilic leukemia comprising administering biaryl meta-pyrimidine compounds having the general structure (A) to a subject in need thereof. The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the JAK kinase family, and various other specific receptor and non-receptor kinases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.